PepGen Inc. Common Stock (PEPG) is a publicly traded Healthcare sector company. As of May 21, 2026, PEPG trades at $1.44 with a market cap of $101.68M and a P/E ratio of -0.67. PEPG moved +5.07% today. Year to date, PEPG is -78.41%; over the trailing twelve months it is -8.86%. Its 52-week range spans $0.88 to $9.94. Analyst consensus is buy with an average price target of $10.17. Rallies surfaces PEPG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Places Partial Clinical Hold on PepGen’s Phase 2 Myotonic Dystrophy Trial: FDA placed a partial hold on PepGen’s Phase 2 FREEDOM2-DM1 trial over pharmacology and toxicology questions, requiring submission of Phase 1 FREEDOM data. PepGen has clearance for FREEDOM2 in South Korea, Australia and New Zealand and plans 5 mg/kg data in Q1 2026 and 10 mg/kg data in H2 2026.
| Metric | Value |
|---|---|
| Price | $1.44 |
| Market Cap | $101.68M |
| P/E Ratio | -0.67 |
| EPS | $-2.12 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.94 |
| 52-Week Low | $0.88 |
| Volume | 300 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-89.66M |
| Gross Margin | 0.00% |
6 analysts cover PEPG: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.17.